BioNTech Investors Face a Dual Narrative: Legal Battle and Financial Crossroads

BioNTech's 2025 financial report and a key patent lawsuit with Moderna create near-term uncertainty as the company pivots its long-term strategy to oncology.

As March unfolds, BioNTech finds itself at a critical juncture defined by two distinct narratives. The company is embroiled in a high-stakes patent litigation with rival Moderna, while simultaneously preparing to release its full-year 2025 financial results. This presents investors with a complex picture: assessing near-term legal and commercial clarity while the firm's long-term valuation thesis remains firmly anchored in its oncology pipeline.

Financial Results Loom: A Bridge to the Future

The company has confirmed it will report its fourth-quarter and full-year 2025 figures on Tuesday, March 10, 2026. A conference call and webcast with a corporate update will accompany the release.

The context for these numbers is crucial. BioNTech ended 2025 with €17.2 billion in cash and investments and had previously updated its 2025 revenue guidance to a range of €2.6 to €2.8 billion. A significant forward-looking statement tempers expectations: The company does not anticipate generating any oncology product revenue in 2026. This declaration elevates the importance of the upcoming report, as market participants will scrutinize management's commentary on cost structures, strategic priorities, and pipeline progress for clues about the bridge to future profitability.

Moderna Patent Dispute: A Clash Over Vaccine Technology

Adding a layer of near-term uncertainty is an active legal fight. BioNTech has filed a lawsuit against Moderna in a U.S. federal court in Delaware. The core allegation is that Moderna's updated COVID-19 vaccine, mNEXSPIKE, infringes on a patent related to the BioNTech/Pfizer shot, Comirnaty.

The legal complaint centers on an mRNA vaccine architecture that, according to BioNTech, allows for a "streamlined" construct designed to work with a lower dosage. BioNTech cites a U.S. patent granted in November 2024. The German biotech is seeking financial damages but has clarified it is not pursuing an injunction to halt sales of the rival vaccine.

The potential financial stakes are substantial. Court documents reference Moderna's COVID-19 vaccine sales, which reached $1.168 billion through the third quarter of 2025. Furthermore, projections suggest mNEXSPIKE could account for 55% of Moderna's COVID vaccine sales during the 2025/2026 respiratory season. BioNTech contends this represents a continuing, willful infringement of its intellectual property. Moderna has stated its intention to mount a defense.

This legal skirmish is reciprocal. Moderna initially sued BioNTech and Pfizer over Comirnaty in 2022, and that separate case remains ongoing.

Oncology: The Long-Term Engine Amid Vaccine Headwinds

The company's strategic focus was outlined at the recent J.P. Morgan Healthcare Conference. Priorities for 2026 include accelerating late-stage oncology programs, advancing combination therapies, and targeting multiple cancer types, including lung, breast, gastrointestinal, genitourinary, and gynecological tumors. BioNTech anticipates having 15 Phase 3 trials underway by the end of 2026, with seven late-stage data readouts expected within the year.

This push is essential as the vaccine commercial landscape grows more challenging. Industry-wide COVID-19 revenue has declined due to lower demand, the shift to a commercial sales model in the U.S. following the end of the public health emergency in May 2023, narrower vaccination recommendations, and growing vaccine hesitancy. These factors define the environment in which BioNTech must stabilize its vaccine business while advancing its oncology assets toward becoming a sustainable revenue stream.

The company's shares closed at €93.30 on Friday.

The March 10 update will thus require BioNTech to address both fronts: demonstrating how vaccine revenues are stabilizing under new market realities and articulating how quickly progress in oncology can translate into a credible financial outlook for the coming years.